Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02051751 |
| Title | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | FRA | ESP |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | United States | Details | |
| Horizon Oncology Center BioAdvance | Lafayette | Indiana | 47905 | United States | Details | |
| Novartis Investigative Site | Toulouse Cedex 9 | 31059 | France | Details | ||
| Novartis Investigative Site | Milano | MI | 20141 | Italy | Details | |
| Novartis Investigative Site | Barcelona | Catalunya | 08035 | Spain | Details |